JP2024539891A5 - - Google Patents

Info

Publication number
JP2024539891A5
JP2024539891A5 JP2024523533A JP2024523533A JP2024539891A5 JP 2024539891 A5 JP2024539891 A5 JP 2024539891A5 JP 2024523533 A JP2024523533 A JP 2024523533A JP 2024523533 A JP2024523533 A JP 2024523533A JP 2024539891 A5 JP2024539891 A5 JP 2024539891A5
Authority
JP
Japan
Prior art keywords
weight
solid dispersion
compound
solvate
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/047769 external-priority patent/WO2023076305A1/en
Publication of JP2024539891A publication Critical patent/JP2024539891A/ja
Publication of JP2024539891A5 publication Critical patent/JP2024539891A5/ja
Pending legal-status Critical Current

Links

JP2024523533A 2021-10-26 2022-10-25 Erk阻害剤を含んでなる組成物 Pending JP2024539891A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163271977P 2021-10-26 2021-10-26
US63/271,977 2021-10-26
PCT/US2022/047769 WO2023076305A1 (en) 2021-10-26 2022-10-25 Compositions comprising an erk inhibitor

Publications (2)

Publication Number Publication Date
JP2024539891A JP2024539891A (ja) 2024-10-31
JP2024539891A5 true JP2024539891A5 (cg-RX-API-DMAC10.html) 2025-10-27

Family

ID=84367494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523533A Pending JP2024539891A (ja) 2021-10-26 2022-10-25 Erk阻害剤を含んでなる組成物

Country Status (8)

Country Link
US (1) US20240415835A1 (cg-RX-API-DMAC10.html)
EP (1) EP4422604A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024539891A (cg-RX-API-DMAC10.html)
KR (1) KR20240089586A (cg-RX-API-DMAC10.html)
CN (1) CN118119381A (cg-RX-API-DMAC10.html)
AU (1) AU2022376165A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235680A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023076305A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068412A1 (en) * 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017068412A1 (en) 2015-10-21 2017-04-27 Otsuka Pharmaceutical Co., Ltd. Benzolactam compounds as protein kinase inhibitors
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound

Similar Documents

Publication Publication Date Title
CN116157391B (zh) 包含egfr抑制剂的药物组合物及其制备方法
EP1778201B1 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
JP7051638B2 (ja) エスシタロプラム医薬組成物
CN118119381A (zh) 包含erk抑制剂的组合物
US12533320B2 (en) Oral sustained-release composition for insoluble drug, and preparation method thereof
WO2013054872A1 (ja) 7-[4-(4-ベンゾ[b]チオフェン-4-イル-ピペラジン-1-イル)ブトキシ]-1H-キノリン-2-オン又はその塩を含む錠剤
JP2020533283A5 (cg-RX-API-DMAC10.html)
CN112022812A (zh) 一种包含杂环类化合物的组合物、其制备方法和应用
JP2018513863A (ja) ブロモドメイン阻害剤
WO2021223480A1 (zh) 一种替格瑞洛控释片及其制备方法
JP6293315B2 (ja) アリサルタン・イソプロキシル固体分散体及び該固体分散体を含有する医薬組成物
CN114096530B (zh) 一种复合物的药物组合物及其制备方法
JP2006501274A (ja) オキシカルバゼピンおよびその誘導体の改良放出製剤
AU2009243734B2 (en) Granulate comprising escitalopram oxalate
CN119300811A (zh) 高剂量因多昔芬制剂和使用方法
MX2013010598A (es) Composiciones farmaceuticas de liberacion controlada de inhibidor de recaptacion de serotonina selectivo.
KR101128891B1 (ko) 로라타딘 및 슈도에페드린을 함유하는 제어 방출 다층정
CN104800184A (zh) 琥珀酸呋罗曲坦缓释剂片
CN114053237A (zh) 一种控释片剂及其制备方法
CN101756981B (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
TWI745598B (zh) 非布司他控釋組合物及其製備方法
JP6787928B2 (ja) リバスチグミン含有徐放出医薬組成物
CN118662470A (zh) 一种非奈利酮胶囊剂及其制备方法
JP2024500545A5 (cg-RX-API-DMAC10.html)
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태